

Table of contents

Acknowledgements	ii
Disclaimer	ii
Abbreviations	iii
Table of Contents	iv
List of Tables	vi
List of Figures	vii
Chapter 1: Introduction	1
1.1 Background to the National Amphetamine-Type Stimulant Strategy	1
1.2 Defining amphetamine-type stimulants	3
1.3 History of amphetamine-type stimulants	5
1.4 Forms of illicit amphetamine-type stimulants	6
1.5 Australian data collections	8
1.6 Availability	9
1.7 Price	12
1.8 Purity	13
1.9 Routes of administration	15
1.10 Summary	17
Chapter 2: Setting the Context	18
2.1 Prevalence of amphetamine-type stimulant use in the general population of Australia	18
2.2 Australian surveys with key consumer groups	20
2.3 Jurisdictional variations	24
2.4 At-risk populations	25
2.5 Summary	32
Chapter 3: Effects of Amphetamine-Type Stimulants	33
3.1 Effects for users	33
3.2 Negative cognitive and psychological effects	34
3.3 Dependence and adverse outcomes	38
3.4 Negative physical health effects	40
3.5 Negative behavioural and social effects	43
3.6 Effects on family and community	50
3.7 Summary	54

Chapter 4: Prevention and Harm Reduction	56
4.1 What is prevention?	56
4.2 Preventing drug use	57
4.3 Reducing associated problems	73
4.4 Challenges of applying prevention and harm reduction strategies to amphetamine-type stimulants	84
4.5 Building the capacity of the workforce to engage in prevention and harm reduction	87
4.6 Summary	88
Chapter 5: Treatment and Service Provision	90
5.1 Amphetamine-type stimulant treatment presentations	90
5.2 Initial engagement	91
5.3 Treatment access and retention	95
5.4 Withdrawal management	98
5.5 Psychosocial interventions	99
5.6 Pharmacotherapy	103
5.7 Other interventions	108
5.8 Managing co-occurring mental health and amphetamine-type stimulant problems	108
5.9 Workforce development	111
5.10 Summary	113
Chapter 6: Law Enforcement	115
6.1 International markets	115
6.2 Domestic methamphetamine production	116
6.3 Precursor regulation	118
6.4 Australian law enforcement	123
6.5 Local drug markets	124
6.6 ATS and crime	126
6.7 Responses to drugs and crime	129
6.8 Multilateral approaches	137
6.9 Priorities in law enforcement	141
6.10 Summary	148
Appendix 1	150
National consultation forums	150
Consultations with key organisations	151
Appendix 2	152
Written submissions	152
References	153

List of tables

Table 1.1: Amphetamine-type stimulants commonly used in Australia	4
Table 1.2: Amphetamine types, forms and routes of administration	7
Table 1.3: Estimated availability and median price of methamphetamine by jurisdiction, 2000-2006	13
Table 2.1: Use of ATS among key sentinel groups in 2006 (%)	21
Table 2.2: Prevalence of methamphetamine use among incarcerated male offenders	23
Table 2.3: Patterns of methamphetamine use by police detainees across jurisdictions	25
Table 3.1: Perceptions of adult police detainees of the effects of drug use on their driving	46
Table 3.2: Violent offending histories for regular amphetamine and heroin users, adult male prisoners (%)	49
Table 3.3: Maternal demographic characteristics of pregnancies to mothers with and without a drug-related diagnosis code, 1998–2002 (%)	51
Table 6.1: Number of clandestine laboratory detections by state and territory, 96/97-05/06	118
Table 6.2: Examples of domestic law enforcement initiatives to address the supply of precursors to the illegal market	120
Table 6.3: Examples of legislative changes in different jurisdictions	121
Table 6.4: Key drug market characteristics for those who paid cash for drugs in the past 30 days, adult police detainees (%)	125
Table 6.5: Attributions for offending career for regular amphetamine and regular heroin users, adult male offenders (%)	128
Table 6.6: Range of juvenile justice outcomes and services available by state and territory, June 2006	135
Table 6.7: Examples of State and Territory law enforcement initiatives	139

List of figures

Figure 1.1: MDMA (ecstasy) tablets	8
Figure 1.2: Number and weight of detections of amphetamine (excluding phenethylamine) at the Australian border, 1995–96 to 2005–06	10
Figure.1.3: Number and weight of detections of phenethylamine (MDMA/ecstasy) at the Australian border, 1995–96 to 2005–06	11
Figure 1.4: Forms of methamphetamine used by recent users, 2004	12
Figure 1.5: Median purity of methamphetamine samples, 2001/02–2005/06	14
Figure 2.1: Percent of general population who have used methamphetamine and heroin in the past 12 months	18
Figure 2.2: Prevalence of ecstasy use in Australia, 1988-2004	20
Figure 2.3: Arrests for drug-related offences	24